These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20349059)

  • 1. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.
    Borkner L; Kaiser A; van de Kasteele W; Andreesen R; Mackensen A; Haanen JB; Schumacher TN; Blank C
    Cancer Immunol Immunother; 2010 Aug; 59(8):1173-83. PubMed ID: 20349059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
    Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
    J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy.
    Tsushima F; Yao S; Shin T; Flies A; Flies S; Xu H; Tamada K; Pardoll DM; Chen L
    Blood; 2007 Jul; 110(1):180-5. PubMed ID: 17289811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis.
    Hamel KM; Cao Y; Wang Y; Rodeghero R; Kobezda T; Chen L; Finnegan A
    Eur J Immunol; 2010 Nov; 40(11):3117-27. PubMed ID: 21061440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses.
    Lin PY; Sun L; Thibodeaux SR; Ludwig SM; Vadlamudi RK; Hurez VJ; Bahar R; Kious MJ; Livi CB; Wall SR; Chen L; Zhang B; Shin T; Curiel TJ
    J Immunol; 2010 Sep; 185(5):2747-53. PubMed ID: 20686128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.
    Martin-Orozco N; Wang YH; Yagita H; Dong C
    J Immunol; 2006 Dec; 177(12):8291-5. PubMed ID: 17142723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.
    Keir ME; Latchman YE; Freeman GJ; Sharpe AH
    J Immunol; 2005 Dec; 175(11):7372-9. PubMed ID: 16301644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
    Durgan K; Ali M; Warner P; Latchman YE
    Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of programmed death 1 ligands by murine T cells and APC.
    Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
    J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade.
    Reynoso ED; Elpek KG; Francisco L; Bronson R; Bellemare-Pelletier A; Sharpe AH; Freeman GJ; Turley SJ
    J Immunol; 2009 Feb; 182(4):2102-12. PubMed ID: 19201863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
    Blank C; Gajewski TF; Mackensen A
    Cancer Immunol Immunother; 2005 Apr; 54(4):307-14. PubMed ID: 15599732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
    Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
    J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft.
    Morita M; Fujino M; Jiang G; Kitazawa Y; Xie L; Azuma M; Yagita H; Nagao S; Sugioka A; Kurosawa Y; Takahara S; Fung J; Qian S; Lu L; Li XK
    Am J Transplant; 2010 Jan; 10(1):40-6. PubMed ID: 19889124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
    Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
    Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4 T-cell help programs a change in CD8 T-cell function enabling effective long-term control of murine gammaherpesvirus 68: role of PD-1-PD-L1 interactions.
    Dias P; Giannoni F; Lee LN; Han D; Yoon S; Yagita H; Azuma M; Sarawar SR
    J Virol; 2010 Aug; 84(16):8241-9. PubMed ID: 20534854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
    Lucas CL; Workman CJ; Beyaz S; LoCascio S; Zhao G; Vignali DA; Sykes M
    Blood; 2011 May; 117(20):5532-40. PubMed ID: 21422469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
    Zhang L; Gajewski TF; Kline J
    Blood; 2009 Aug; 114(8):1545-52. PubMed ID: 19417208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.
    Gu T; Zhu YB; Chen C; Li M; Chen YJ; Yu GH; Ge Y; Zhou SY; Zhou H; Huang Y; Qiu YH; Zhang XG
    Cell Mol Immunol; 2008 Feb; 5(1):33-9. PubMed ID: 18318992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
    Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
    J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.